BURJEEL-MEDICAL-CITY
23.5.2023 16:25:25 CEST | Business Wire | Press release
Burjeel Medical City, the flagship facility of Burjeel Holdings, has launched an Advanced Gynecology Institute (AGI) designed to offer multidisciplinary healthcare solutions to women of all ages. The launch comes just months after the hospital joined hands with the globally renowned Franco-European Multidisciplinary Institute of Endometriosis Academy (IFEM Endo). Three specialized clinics of the hospital - Gynecological Oncology, IFEM Endo Middle East Clinic, and Complex Gynecology Care - will come under AGI.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230523005817/en/
H.E. Dr. Maitha Bint Salem Al Shamsi, Minister of State, UAE Government, inaugurating Advanced Gynecology Institute at Burjeel Medical City (Photo: AETOSWire)
Prof. Horace Roman, a renowned endometriosis surgeon and founding member of IFEM Endo, will be heading the institute. Dr. Benjamin Merlot, Consultant - Obstetrics and Gynecology and founding member of IFEM Endo, Dr. Sandesh Kade, Specialist - Obstetrics and Gynecology, Dr. Monica Chauhan, Specialist - Obstetrics & Gynecology, and Dr. Jafaru Abu, Consultant Gynecological Oncology Surgery, are other members of the team.
“The institute's launch is a significant milestone in women’s healthcare in the region. Women’s health needs are diverse and complex, requiring a holistic approach to ensure that each patient receives personalized care that meets her specific needs,” said Prof. Roman, adding that the expert team will also be involved in clinical research and training.
AGI possesses state-of-the-art surgical suites with the latest technology, allowing for advanced procedures such as laparoscopic and robotic surgeries. In addition to treating gynecological cancers, AGI focuses on preserving reproductive function in patients, and improving the quality of life for patients with advanced or recurrent gynecological malignancies. The institute also offers highly advanced minimally invasive surgeries for endometriosis.
“The institute showcases our commitment to excellence and cements our position as a leader in complex care. With a focus on specialized clinics, and personalized care, the institute is poised to make a significant impact on the healthcare sector in the UAE and beyond,” said Mr. John Sunil, CEO, Burjeel Holdings.
About Burjeel Medical City
Burjeel Medical City is a 400-bed multi-specialty hospital and quaternary care center located in Abu Dhabi, UAE. It offers high-quality specialized treatment and complex care in over 40 adult and pediatric specialties, aided by state-of-the-art medical technology and an international team of experts. Find more information at https://www.burjeelmedicalcity.com/
*Source: AETOSWire
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230523005817/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
IQM Secures €50M Financing to Accelerate Global Growth30.3.2026 08:00:00 CEST | Press release
€50 million financing package from funds and accounts managed by BlackRock will support IQM to scale operations, accelerate product development, and strengthen its market position. The facility will support acceleration of IQM’s technology roadmap, fuel R&D, support entry into additional markets, and advance IQM’s leadership in quantum computing as IQM prepares for public listing. IQM Finland Oy, a global leader in full-stack superconducting quantum computers (“IQM”, “IQM Quantum Computers” or the “Company”), today announced it has secured a €50 millionfinancing package from funds and accounts managed by BlackRock. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260329996942/en/ IQM Radiance quantum computer is located in IQM's showroom in Espoo, Finland. This facility will support acceleration of IQM’s technology roadmap, fuel R&D, support entry into additional markets, and advance IQM’s leadership in quantum computing. This
Bureau Veritas and Trade Technologies Join Forces to Streamline Global Trade Operations30.3.2026 07:45:00 CEST | Press release
Bureau Veritas, a global leader in Testing, Inspection, and Certification services (TIC), through its Swiss branch Government Services Division, is pleased to announce a strategic agreement with Trade Technologies, the leading provider of trade finance automation, connectivity and transaction management services. This collaboration is a significant step toward reducing the complexities of international trade operations, particularly in regions where regulatory and inspection controls remain stringent. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260329411683/en/ Addressing Critical Trade Finance Challenges The agreement comes at a pivotal time for global trade. Letters of Credit (LCs) continue to serve as essential instruments in international commerce, particularly across the Middle East and Africa, where counterparty risk, foreign exchange controls, sanctions exposure, and regulatory oversight face ongoing challenges. In
Consortium Led by Axelspace Selected for Japan’s Space Strategy Fund Project “Technology to Enhance Capability of Next Generation Earth Observation Satellites”30.3.2026 01:35:00 CEST | Press release
~ Creating Climate Solutions and New Market Opportunities through Source-Specific CO2 Emission and Uptake Monitoring via Satellite Constellation and Aircraft ~ Axelspace Corporation, Meisei Electric Co., Ltd., ANA HOLDINGS INC., and JIJ Inc. are pleased to announce that their jointly proposed technology development project has been selected for Japan Aerospace Exploration Agency (JAXA)’s Space Strategy Fund under the theme “Technology to Enhance Capability of Next Generation Earth Observation Satellites.” This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260323044518/en/ Conceptual Diagram of the project. Under this Space Strategy Fund initiative, spectrometers will be newly developed and demonstrated in orbit. In the future, the project envisions the establishment of a satellite constellation capable of observations at different times of the day. Project Summary (Planned) Technology Development Theme: Technology to Enhance Cap
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom